




Fermathron

Fermathron is developed for pain and stiffness treatments of knees and other synovial joints by providing support and lubrication.



Market:

Extensive need for this disease creates significant opportunity for drug developers, according to a new report from Decision Resources. The market for disease-modifying osteoarthritis drugs will experience exponential growth, increasing from \$477 million in 2007 to nearly \$3.8 billion in 2017.

Hyaluronic acid:

Fermathron is a sodium hyaluronate viscosupplement. The body own hyaluronan is a natural material which is present in nearly all connective tissue matrices of vertebrate organisms.

Osteoarthritis:

Osteoarthritis affects the moveability of joints, especially of weight bearing joints like the knee. The disease results in alterations of the composition of the synovial fluids which leads to the reduction of physiological protective functions of the synovial fluid. In the end less lubrication of joints causes less movability and intensive pain.

Application:

Fermathron is presented as a clear sterile solution of sodium hyaluronate in a phosphate buffered saline.

2 ml of Fermathron are delivered in disposable glass syringe, ready to use. The outer surface of the pre filled syringe is sterilized by ethylene oxide.

The recommended dosage of Fermathron

depends on the severity of the degenerative or traumatic change of the synovial joint. Mild or moderate osteoarthritis of the knee joint are treated with 3-5 injections of Fermathron per week.

The injection has to be used in sterile conditions. In this connection the skin has to be cleaned with antiseptic.

